• Markets
    • icon
  • Companies
PER · ASX

Percheron Therapeutics Limited (ASX:PER)

AU$0.093

 0.003 (3.333%)
ASX:Live
16/09/2024 02:58:49 PM
Recent Earnings upgrade HALO Price Momentum HALO Ords HALO Momentum HALO Earnings Momentum +4
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

PER Overview

PER Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Weak

Earnings

Very Weak

Growth

Earnings

Neutral

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Weak

About PER

Website

Percheron Therapeutics Limited

Telephone

61.3.9827.8999

Address

Level 30 35 Collins Street Collins Place Melbourne, Victoria (VIC) 3000

Description

Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the ATL1102, and ATL1103 segments. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. The ATL1103 segment refers to atesidorsen is an antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin. The company was founded on November 13, 2000 and is headquartered in Toorak, Australia.

PER Price Chart

Key Stats

Market Cap

AU$77.53M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.05 - 0.11

Trade Value (12mth)

AU$13,551.00

1 week

9.76%

1 month

12.5%

YTD

47.54%

1 year

30.43%

All time high

1.85

Key Fundamentals

EPS 3 yr Growth

-9.40%

EBITDA Margin

N/A

Operating Cashflow

-$10m

Free Cash Flow Return

-104.40%

ROIC

-123.00%

Interest Coverage

-4,107.90

Quick Ratio

2.80

Other Data

Shares on Issue (Fully Dilluted)

902m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

PER Announcements

Latest Announcements

Date Announcements

04 September 24

Percheron Therapeutics Limited Corporate Presentation

×

Percheron Therapeutics Limited Corporate Presentation

03 September 24

ATL1102 Shows Preclinical Activity in Autoimmune Epilepsy

×

ATL1102 Shows Preclinical Activity in Autoimmune Epilepsy

29 August 24

Appendix 4E and Annual Report

×

Appendix 4E and Annual Report

29 August 24

Appendix 4G and Corporate Governance Statement

×

Appendix 4G and Corporate Governance Statement

29 August 24

Notice of date of AGM and other relevant dates

×

Notice of date of AGM and other relevant dates

31 July 24

Quarterly Activities Report and Appendix 4C

×

Quarterly Activities Report and Appendix 4C

04 July 24

Notification regarding unquoted securities - PER

×

Notification regarding unquoted securities - PER

17 June 24

Deborah Ambrosini appointed as CFO & Company Secretary

×

Deborah Ambrosini appointed as CFO & Company Secretary

03 June 24

Percheron appoints Dr Cathryn Clary as Chief Medical Advisor

×

Percheron appoints Dr Cathryn Clary as Chief Medical Advisor

31 May 24

Percheron to present at 2024 BIO International Convention

×

Percheron to present at 2024 BIO International Convention

29 May 24

Phase IIb study of ATL1102 in DMD completes recruitment

×

Phase IIb study of ATL1102 in DMD completes recruitment

27 May 24

Preliminary Results of 9 Month Toxicology Study of ATL1102

×

Preliminary Results of 9 Month Toxicology Study of ATL1102

20 May 24

US Patent Granted for ATL1102 in Duchenne muscular dystrophy

×

US Patent Granted for ATL1102 in Duchenne muscular dystrophy

06 May 24

WHO selects proposed INN for ATL1102

×

WHO selects proposed INN for ATL1102

30 April 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

26 April 24

Change in substantial holding

×

Change in substantial holding

02 April 24

ATL1102 Clinical Trial Update

×

ATL1102 Clinical Trial Update

04 March 24

ATL1102 Data presented at MDA Annual Conference

×

ATL1102 Data presented at MDA Annual Conference

28 February 24

Half Yearly Report and Accounts

×

Half Yearly Report and Accounts

26 February 24

Percheron Therapeutics Limited Corporate Presentation

×

Percheron Therapeutics Limited Corporate Presentation

21 February 24

Change of Registered Office and Principal Place of Business

×

Change of Registered Office and Principal Place of Business

12 February 24

Receipt of R&D Tax incentive payment

×

Receipt of R&D Tax incentive payment

31 January 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

29 January 24

ATL1102 DMD Phase IIA Final Data Published

×

ATL1102 DMD Phase IIA Final Data Published

PER Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.01 -0.02 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.01 -0.02 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 38.3 -84.8 20.6 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.01 -0.02 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 27.0 -96.7 21.6 Lock Lock Lock
     Yield % Lock Lock Lock Lock -23.9 -31.1 -20.2 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.03 0.01 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.03 0.01 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 217.1 -52.9 -30.3 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 634 669 881 Lock Lock Lock
Basic m Lock Lock Lock Lock 634 669 881 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 8 13 15 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 13.6 -6.7 16.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -8 -13 -15 Lock Lock Lock
     Growth % Lock Lock Lock Lock 12.3 -76.1 -11.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -8 -13 -15 Lock Lock Lock
     Growth % Lock Lock Lock Lock 12.3 -75.3 -11.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -8 -13 -14 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -2 -2 -2 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -6 -11 -12 Lock Lock Lock
     Growth % Lock Lock Lock Lock 27.9 -95.8 -4.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -8 -8 -10 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 21 0 11 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -8 -8 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -33.7 -4.8 -23.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 19 11 12 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 22 13 15 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -19 -11 -12 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 3 5 Lock Lock Lock
Equity $m Lock Lock Lock Lock 21 10 9 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 21 10 9 Lock Lock Lock
     Growth % Lock Lock Lock Lock 257.3 -52.9 -6.6 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -25.9 -88.6 -82.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -27.5 -114.1 -127.3 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -55.5 -84.8 -152.5 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -42.7 -72.7 -123.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -57.3 -52.1 -104.4 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -631.7 -1,624.9 -4,107.9 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 2.5 0.8 0.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -89.9 -108.5 -126.3 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 19.1 4.5 2.8 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 19.1 4.5 2.8 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 86.6 86.4 82.0 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -672.4 -289.8 -196.3 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -25.9 -88.6 -82.0 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.3 1.6 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -27.5 -114.1 -127.3 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -27.5 -114.1 -127.3 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 999.2 2,596.0 10,928.1 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -999.2 -2,596.0 -10,928.1 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PER Shortsell

Frequently Asked Questions

The current share price of Percheron Therapeutics Limited (PER:ASX) is AU$0.093.
The 52-week high share price for Percheron Therapeutics Limited (PER:ASX) is AU$0.11.
The 52-week low share price for Percheron Therapeutics Limited (PER:ASX)? is AU$0.05.
Percheron Therapeutics Limited (PER:ASX) does not pay a dividend.
Percheron Therapeutics Limited (PER:ASX) does not pay a dividend.
Percheron Therapeutics Limited (PER:ASX) has a franking level of 0.0%.
Percheron Therapeutics Limited (PER:ASX) is classified in the Healthcare.
The current P/E ratio for Percheron Therapeutics Limited (PER:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.